Trials / Completed
CompletedNCT00972725
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 52 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
Detailed description
The Protocol Posting has been updated following Protocol amendment 1, October 2009.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' HIV vaccine (732461) | 1 dose intramuscular injection |
| DRUG | Chloroquine | One dose of 300 mg |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2010-10-04
- Completion
- 2010-10-04
- First posted
- 2009-09-07
- Last updated
- 2018-08-17
- Results posted
- 2017-04-13
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00972725. Inclusion in this directory is not an endorsement.